Moleculern™ – The Next Evolution in Drug DiscoveryScreening each Moleculern™ fragment against a curated protein target library has resulted in 600K real/empirical data points and scaffold-like compounds that can be used to design new drug candidates and to accelerate the discovery process. Our empirically rich Moleculern™ technology is rapidly creating, discovering, and developing novel pre-clinical to clinical stage agents. Our modern chemical biology approach coupled with our advanced machine learning and AI-backed platform accelerates discoveries by mapping hot-spots, computing ligand properties and building accurate empirical models which translate into active, safe, and efficacious novel chemical entities (NCEs) of future medicines.Biolexis is developing better and safer drugs faster through Moleculern™:    Accelerates drug discovery/development to new therapeutics     Shortens the path to the clinic to increase the probability of success    Expedites to First-In-Human (FIH) clinical trials    Facilitates delivery of medicines to patients worldwide

Biolexis Therapeutics, Inc.

Sirion Biotech is a biotechnology company specializing in viral vector technologies for gene delivery and gene therapy applications.

Sirion Biotech

Sanyou Biopharmaceuticals is a biotechnology company focused on the development of innovative biopharmaceutical products for various medical needs.

Sanyou Biopharmaceuticals

Pure Biologics is a biotechnology company that specializes in the development of novel biologic drugs and therapies for treating various diseases.

Pure Biologics

Metagen Therapeutics is a biotechnology company focused on the development of microbiome-based therapeutics for addressing health challenges.

Metagen Therapeutics

Centivax is a biotechnology company specializing in the development of innovative vaccines and immunotherapies for various diseases.

Centivax

BioLexis is a biotechnology company that specializes in the development of innovative therapeutics and diagnostics. The company leverages cutting-edge research and development to address complex health challenges, focusing on areas with significant unmet medical needs.

BioLexis

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 14, 2024 8:46 AM	772b9c2b
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 14, 2024 8:46 AM	fa31bc4e
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:BIOLEXISTX

BioLexis